ALT Quote, Financials, Valuation and Earnings

Rhythm Pharmaceuticals, Inc. has a net margin of -380280% compared to Altimmune, Inc.'s net margin of -103.13%. Altimmune, Inc.'s return on equity of -56.24% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -509.34%.

Altimmune, Inc. has a consensus price target of $17.75, signalling upside risk potential of 328.74%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $139.00 which suggests that it could grow by 23.72%. Given that Altimmune, Inc. has higher upside potential than Rhythm Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than Rhythm Pharmaceuticals, Inc..

Altimmune, Inc. has a beta of -0.029, which suggesting that the stock is 102.89% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 1.963, suggesting its more volatile than the S&P 500 by 96.257%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $5K, which are smaller than Rhythm Pharmaceuticals, Inc. quarterly revenues of $51.3M. Altimmune, Inc.'s net income of -$19M is higher than Rhythm Pharmaceuticals, Inc.'s net income of -$52.9M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 15,865.35x versus 41.02x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals, Inc. has a net margin of -380280% compared to Altimmune, Inc.'s net margin of --. Altimmune, Inc.'s return on equity of -56.24% beat Terns Pharmaceuticals, Inc.'s return on equity of -29.05%.

Altimmune, Inc. has a consensus price target of $17.75, signalling upside risk potential of 328.74%. On the other hand Terns Pharmaceuticals, Inc. has an analysts' consensus of $53.56 which suggests that it could grow by 28.96%. Given that Altimmune, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than Terns Pharmaceuticals, Inc..

Altimmune, Inc. has a beta of -0.029, which suggesting that the stock is 102.89% less volatile than S&P 500. In comparison Terns Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Terns Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $5K, which are larger than Terns Pharmaceuticals, Inc. quarterly revenues of --. Altimmune, Inc.'s net income of -$19M is higher than Terns Pharmaceuticals, Inc.'s net income of -$24.6M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Terns Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 15,865.35x versus -- for Terns Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -380280% compared to Altimmune, Inc.'s net margin of --. Altimmune, Inc.'s return on equity of -56.24% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Altimmune, Inc. has a consensus price target of $17.75, signalling upside risk potential of 328.74%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 156.49%. Given that Altimmune, Inc. has higher upside potential than Viking Therapeutics, Inc., analysts believe Altimmune, Inc. is more attractive than Viking Therapeutics, Inc..

Altimmune, Inc. has a beta of -0.029, which suggesting that the stock is 102.89% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $5K, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Altimmune, Inc.'s net income of -$19M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 15,865.35x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

X4 Pharmaceuticals, Inc. has a net margin of -380280% compared to Altimmune, Inc.'s net margin of -1689.24%. Altimmune, Inc.'s return on equity of -56.24% beat X4 Pharmaceuticals, Inc.'s return on equity of -279.19%.

Altimmune, Inc. has a consensus price target of $17.75, signalling upside risk potential of 328.74%. On the other hand X4 Pharmaceuticals, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 94.18%. Given that Altimmune, Inc. has higher upside potential than X4 Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than X4 Pharmaceuticals, Inc..

Altimmune, Inc. has a beta of -0.029, which suggesting that the stock is 102.89% less volatile than S&P 500. In comparison X4 Pharmaceuticals, Inc. has a beta of 0.421, suggesting its less volatile than the S&P 500 by 57.861%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. X4 Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. X4 Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $5K, which are smaller than X4 Pharmaceuticals, Inc. quarterly revenues of $1.8M. Altimmune, Inc.'s net income of -$19M is higher than X4 Pharmaceuticals, Inc.'s net income of -$29.8M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while X4 Pharmaceuticals, Inc.'s PE ratio is 0.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 15,865.35x versus 1.95x for X4 Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.